While PPARγ agonists are known to enhance insulin sensitivity and aid in managing type 2 diabetes, their clinical use is often restricted due to significant side effects, including an increased risk of heart failure, weight gain, bone fragility, edema, and cancer. This evidence concerns the gene PPARG and type 2 diabetes mellitus.